Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

Cullinan Therapeutics (CGEM) will host an event for analysts and institutional investors at the ASCO Annual Meeting on June 1, following the oral presentation of Phase 2b REZILIENT1 trial results for zipalertinib in EGFR exon20 insertion NSCLC. Additionally, the company's Chief Medical Officer, Jeffrey Jones, will participate in a panel at the Jefferies Global Healthcare Conference on June 4, with CEO Nadim Ahmed and Dr. Jones presenting on June 5; webcasts will be available on the company's investor relations website.

Analysis

Cullinan Therapeutics (CGEM) is set for heightened investor scrutiny with its scheduled management presentations at the 2025 ASCO Annual Meeting and the Jefferies 2025 Global Healthcare Conference. A pivotal event is the company-hosted session for analysts and institutional investors on June 1, 2025, at ASCO, which will follow the oral presentation of results from the pivotal Phase 2b REZILIENT1 trial of zipalertinib in patients with EGFR exon20 insertion NSCLC (Abstract #8503). This data release for zipalertinib is particularly significant given Cullinan's strategy to develop a diversified portfolio of potentially best-in-class or first-in-class modality-agnostic targeted therapies. Subsequent engagements include a panel participation by the Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., on cell therapy and T-cell engagers on June 4, and a company presentation by CEO Nadim Ahmed and Dr. Jones at the Jefferies conference on June 5. The reported "moderately positive" sentiment (0.5 score) and market impact score of 0.6 suggest that the market anticipates these updates, especially the zipalertinib trial results, as potentially significant for the company's outlook and valuation. The availability of webcasts for these key events ensures broad dissemination of information crucial for assessing the progress of Cullinan's clinical pipeline.

Key Decisions for Investors

• Investors should prioritize monitoring the Phase 2b REZILIENT1 trial results for zipalertinib, to be presented at ASCO on June 1, 2025, as this data is a critical near-term catalyst for CGEM.
• The clinical outcomes and subsequent management commentary from both the ASCO and Jefferies conference events are likely to materially impact CGEM's stock performance and investor perception of its valuation, necessitating a thorough evaluation of zipalertinib's potential.
• Consider these upcoming presentations as key opportunities to assess the advancement of Cullinan's lead oncology asset and to gain further insight into the company's overall development strategy for its diversified clinical-stage portfolio.